Methods for determining the prognosis for patients with a prostate neoplastic condition

A method of determining a prognosis for survival for a patient with a prostate neoplastic condition, comprising:

• (a) measuring the level of XIAP in a neoplastic prostate cell-containing sample from said patient, and
• (b) comparing the level of XIAP in said sample to a reference level of XIAP,
• wherein an increased level of XIAP in said sample correlates with increased survival of said patient.

A method of determining a prognosis for survival for a patient with a prostate neoplastic condition, comprising:

• (a) measuring the level of cIAP2 in a neoplastic prostate cell-containing sample from said patient, and
• (b) comparing the level of cIAP2 in said sample to a reference level of cIAP2,
• wherein an increased level of cIAP2 in said sample correlates with decreased survival of said patient.

A method of determining a prognosis for survival for a patient with a prostate neoplastic condition, comprising:

• (a) measuring the level of cIAP1 in a neoplastic prostate cell-containing sample from said patient, and
• (b) comparing the level of cIAP1 in said sample to a reference level of cIAP1,
• wherein an increased level of cIAP1 in said sample correlates with decreased survival of said patient.

A method of determining a prognosis for survival for a patient with a prostate neoplastic condition, comprising:

• (a) measuring the level of two or more IAPs selected from the group consisting of XIAP, cIAP1, and cIAP2 in a neoplastic prostate cell-containing sample from said patient, and
• (b) comparing the level of said two or more IAPs in said sample to a reference level of said IAPs,
• wherein an increased level of XIAP and decreased level of any of cIAP1 or cIAP2 in said sample correlates with increased survival of said patient.

A method of determining a prognosis for survival for a patient with a prostate neoplastic condition, comprising:

• (a) measuring a level of an IAP selected from the group consisting of XIAP, cIAP1, and cIAP2 in a neoplastic cell-containing sample from said patient, and
• (b) classifying said patient as belonging to either a first or second group of patients, wherein said first group of patients having a high level of an IAP is classified as having a different likelihood of suffering prostate disease recurrence or spread than said second group of patients having a low level of an IAP.